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Abstract
Background: In cancer research, the association between a gene and clinical outcome suggests
the underlying etiology of the disease and consequently can motivate further studies. The recent
availability of published cancer microarray datasets with clinical annotation provides the
opportunity for linking gene expression to prognosis. However, the data are not easy to access and
analyze without an effective analysis platform.
Description: To take advantage of public resources in full, a database named "PrognoScan" has
been developed. This is 1) a large collection of publicly available cancer microarray datasets with
clinical annotation, as well as 2) a tool for assessing the biological relationship between gene
expression and prognosis. PrognoScan employs the minimum P-value approach for grouping
patients for survival analysis that finds the optimal cutpoint in continuous gene expression
measurement without prior biological knowledge or assumption and, as a result, enables systematic
meta-analysis of multiple datasets.
Conclusion: PrognoScan provides a powerful platform for evaluating potential tumor markers and
therapeutic targets and would accelerate cancer research. The database is publicly accessible at
http://gibk21.bse.kyutech.ac.jp/PrognoScan/index.html.
Background
A number of genes are recognized as being potentially rel-
evant to cancers. One way to evaluate such genes is to
assess their relationship to prognosis. At present, many
cancer microarray datasets with clinical annotation have
become available in the public domain and provide vast
opportunities to link gene expression to prognosis. How-
ever, the data are not easy to access and analyze without
an effective analysis platform.
Standard survival analysis consists of two steps: 1) group-
ing patients and 2) comparing the risk difference of the
groups. When conducting survival analysis based on con-
tinuous measurement such as gene expression, determi-
nation of the appropriate cutpoints for groupings remains
a critical and difficult task. Thus, although two pioneer
databases, ITTACA [1] and REMBRANDT http://rem
brandt.nci.nih.gov, have provided survival analysis func-
tionality with user defined cutpoints for several focused
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cancer microarray datasets, researchers without prior bio-
logical knowledge or assumptions for the gene may end
up using an arbitrary threshold (e.g. median, tertile, quar-
tile) that does not necessarily reflect the biology of the
gene or may laboriously test a number of possible cut-
points.
The minimum P-value approach is a comprehensive
method to find the optimal risk separation cutpoint in
continuous measurements and have shown the utility in
the analyses of tumor size [2], cell cycle phase estimation
measurement [3], and gene copy number [4]. In addition,
it is intuitive for oncologists, and thus, a systematic appli-
cation of this approach to gene expression from microar-
ray seems logical. Recent studies have reported expression
thresholds at which the gene becomes a contributor to the
development of the cancer such as Bub1 for tumorigenesis
[5], HOXB4 for cellular transformation [6], and MYC for
tumor maintenance [7], and provided a rationale for the
application to gene expression. Thus, we developed "Prog-
noScan", a database featuring a large collection of pub-
licly available cancer microarray datasets with clinical
annotation and a tool for assessing the relationship
between gene expression and prognosis using the mini-
mum P-value approach. This database enables systematic
meta-analysis of the prognostic value of a gene in multiple
datasets and consequently will accelerate cancer research.
Construction and content
Data collection
Cancer microarray datasets with clinical annotation were
intensively collected from the public domain including
Gene Expression Omnibus (GEO) [8], ArrayExpress [9]
and individual laboratory web sites, under the following
criteria: 1) includes patient information on survival event
and time, 2) contains large enough sample sizes to enable
survival analysis, 3) is derived from a 'whole genome'
platform and has no values missing so quantile normali-
zation will function properly and 4) is derived from a plat-
form for which probe annotation for a public identifier
(e.g. gene symbol, GenBank accession number, UniGene
ID) is available. As of February 2009, the collection
included more than 40 datasets of various cancer types
spanning a wide range of cancers including bladder,
blood, breast, brain, esophagus, head and neck, kidney,
lung, and ovarian (Table 1) [10-35], far more comprehen-
sive than both ITTACA, which focuses on bladder cancer,
breast cancer and uveal melanoma, and REMBRANDT,
which specializes in brain cancers. Because some samples
were used more than once by more than one study, the
origin of the samples was checked. Sample duplications
within a dataset were dealt with by leaving one represent-
ative arbitrary. Sample overlaps among datasets were
accepted, because the study design designated by each
contributor may be of value. The collected microarray
datasets were standardized by using quantile normaliza-
tion. Probe annotations were retrieved from GEO and
ArrayExpress. Each probe was mapped to an Entrez Gene
ID by querying the accompanied public identifier in Uni-
Gene database. The information in the dataset was manu-
ally curated and includes 1) study design-cohort, cancer
type, subtype, endpoint, therapy history and pathological
parameters-and 2) experimental procedure-sample prepa-
ration, storage, array type and signal processing method.
To assess prognostic value of genes in various contexts,
available endpoints such as overall survival (OS), recur-
rence free survival (RFS), event free survival (EFS), and
distant-metastasis free survival (DMFS) were adopted as
much as possible. All tables were relationally linked and
stored in the MySQL server.
Data analysis
Survival analysis in PrognoScan employs the minimum P-
value approach [2] to find the cutpoint in continuous
gene expression measurement for grouping patients. First,
patients are ordered by expression value of a given gene.
Next, patients are divided into two (high and low) expres-
sion groups at all potential cutpoint, and the risk differ-
ences of the two groups are estimated by log-rank test.
Then, optimal cutpoint that gives the most pronounced P-
value (Pmin) is selected.
This exploratory approach, however, is known to cause
inflation of a type I error because it conducts multiple cor-
related testing [36-38]. Thus, P-value correction is con-
ducted to control the error rate using the following
formula [39].
where z is the (1 - Pmin /2)-quantile of the standard normal
distribution, φ denotes the standard normal density func-
tion, and [ε, 1 - ε] denote the range of the quantile consid-
ered to be cutpoints. PrognoScan uses ε = 0.1 to avoid
small groupings from cutpoints of < 0.1 or > 0.9 quantile.
For any given gene, this cutpoint determination and prog-
nostic value assessment can be applied to all possible
combinations of dataset, endpoint and probe. For con-
venience, we term each combination as "test". Note that,
because probe design for each gene differs, the number of
possible tests varies according to the gene. For statistical
analysis and visualization, R packages http://www.r-
project.org are used.
Utility
The top page of PrognoScan is quite simple and the user
need only input gene identifier(s) (Fig. 1A). To show the
features of the database and its utility, we give three meta-
analysis examples. The first example is MKI67, a well
known tumor proliferation marker. The prognostic value
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Table 1: Dataset content from PrognoScan
Dataset Cancer type Subtype Cohort Author/
Contributor
Array type n Data source
GSE13507 Bladder cancer Transitional cell 
carcinoma
Cheongju Kim Human-6 v2 n = 165 GEO
GSE5287 Bladder cancer Aarhus (1995–2004) Als et al. [10] HG-U133A n = 30 GEO
GSE12417-GPL570 Blood cancer AML AMLCG (2004) Metzeler et al. [11] HG-U133_Plus_2 n = 79 GEO
GSE12417-GPL96 Blood cancer AML AMLCG (1999–2003) Metzeler et al. [11] HG-U133A n = 163 GEO
GSE12417-GPL97 Blood cancer AML AMLCG (1999–2003) Metzeler et al. [11] HG-U133B n = 163 GEO
GSE8970 Blood cancer AML San Diego Raponi et al. [12] HG-U133A n = 34 GEO
GSE4475 Blood cancer B-cell lymphoma Berlin (2003–2005) Hummel et al. [13] HG-U133A n = 158 GEO
E-TABM-346 Blood cancer DLBCL GELA (1998–2000) Jais et al. [14] HG-U133A n = 53 ArrayExpress
GSE2658 Blood cancer Multiple myeloma Arkansas Zhan et al. [15] HG-U133_Plus_2 n = 559 GEO
E-TABM-158 Breast cancer UCSF, CPMC (1989–1997) Chin et al. [16] HG-U133A n = 129 ArrayExpress
GSE11121 Breast cancer Mainz (1988–1998) Schmidt et al. [17] HG-U133A n = 200 GEO
GSE1378 Breast cancer MGH (1987–2000) Ma et al. [18] Arcturus 22 k n = 60 GEO
GSE1379 Breast cancer MGH (1987–2000) Ma et al. [18] Arcturus 22 k n = 60 GEO
GSE1456-GPL96 Breast cancer Stockholm (1994–1996) Pawitan et al. [19] HG-U133A n = 159 GEO
GSE1456-GPL97 Breast cancer Stockholm (1994–1996) Pawitan et al. [19] HG-U133B n = 159 GEO
GSE2034 Breast cancer Rotterdam (1980–1995) Wang et al. [20] HG-U133A n = 286 GEO
GSE2990 Breast cancer Uppsala, Oxford Sotiriou et al. [21] HG-U133A n = 187 GEO
GSE3143 Breast cancer Duke Bild et al. [22] HG-U95A n = 158 GEO
GSE3494-GPL96 Breast cancer Uppsala (1987–1989) Miller et al. [23] HG-U133A n = 236 GEO
GSE3494-GPL97 Breast cancer Uppsala (1987–1989) Miller et al. [23] HG-U133B n = 236 GEO
GSE4922-GPL96 Breast cancer Uppsala (1987–1989) Ivshina et al. [24] HG-U133A n = 249 GEO
GSE4922-GPL97 Breast cancer Uppsala (1987–1989) Ivshina et al. [24] HG-U133B n = 249 GEO
GSE6532-GPL570 Breast cancer GUYT Loi et al. [25] HG-U133_Plus_2 n = 87 GEO
GSE7378 Breast cancer UCSF Zhou et al. [26] U133AAofAv2 n = 54 GEO
GSE7390 Breast cancer Uppsala, Oxford, Stockholm, IGR, 
GUYT, CRH (1980–1998)
Desmedt et al. [27] HG-U133A n = 198 GEO
GSE7849 Breast cancer Duke (1990–2001) Anders et al. [28] HG-U95A n = 76 GEO
GSE9195 Breast cancer GUYT2 Loi et al. [25] HG-U133_Plus_2 n = 77 GEO
GSE9893 Breast cancer Montpellier, Bordeaux, Turin (1989–
2001)
Chanrion et al. [29] MLRG Human 21 K 
V12.0
n = 155 GEO
GSE11595 Esophagus cancer Adenocarcinoma Sutton Giddings CRUKDMF_22 
K_v1.0.0
n = 34 GEO
GSE7696 Glioma Glioblastoma Lausanne Murat et al. [30] HG-U133_Plus_2 n = 70 GEO
GSE4271-GPL96 Glioma MDA Phillips et al. [31] HG-U133A n = 77 GEO
GSE4271-GPL97 Glioma MDA Phillips et al. [31] HG-U133B n = 77 GEO
GSE2837 Head and neck 
cancer
Squamous cell 
carcinoma
VUMC, VAMC, UTMDACC (1992–
2005)
Chung et al. [32] U133_X3P n = 28 GEO
HARVARD-LC Lung cancer Adenocarcinoma Harvard Beer et al. [33] HG-U95A n = 84 Author's web site
MICHIGAN-LC Lung cancer Adenocarcinoma Michigan (1994–2000) Beer et al. [33] HuGeneFL n = 86 Author's web site
GSE11117 Lung cancer NSCLC Basel Baty Novachip human 34.5 k n = 41 GEO
GSE3141 Lung cancer NSCLC Duke Bild et al. [22] HG-U133_Plus_2 n = 111 GEO
GSE4716-GPL3694 Lung cancer NSCLC Nagoya (1995–1996) Tomida et al. [34] GF200 n = 50 GEOB
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GSE4716-GPL3696 Lung cancer NSCLC Nagoya (1995–1996) Tomida et al. [34] GF201 n = 50 GEO
GSE8894 Lung cancer NSCLC Seoul Son HG-U133_Plus_2 n = 138 GEO
GSE4573 Lung cancer Squamous cell 
carcinoma
Michigan (1991–2002) Raponi et al. [35] HG-U133A n = 129 GEO
DUKE-OC Ovarian cancer Duke Bild et al. [22] HG-U133A n = 134 Author's web site
GSE8841 Ovarian cancer Milan Mariani G4100A n = 83 GEO
E-DKFZ-1 Renal cell carcinoma RZPD Sueltmann A-RZPD-20 n = 74 ArrayExpress
Abbreviations: AML, Acute myelocytic leukemia; DLBCL, Diffuse large B-cell lymphoma; NSCLC, Non-small cell lung cancer
Table 1: Dataset content from PrognoScan (Continued)BMC Medical Genomics 2009, 2:18 http://www.biomedcentral.com/1755-8794/2/18
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of MKI67 protein expression has been reported for many
types of malignant tumor including brain, breast, and
lung cancer and a few exceptions for certain tumors such
as non-Hodgkin's lymphoma [40]. When given the gene,
PrognoScan displays a summary in table format of tests
for the gene with columns for dataset, cancer type, sub-
type, endpoint, cohort, contributor, array type, probe ID,
number of patient, optimal cutpoint, Pmin and Pcor as Fig.
1B for MKI67 (shown in full in Additional file 1). In the
table, 52 out of 152 tests showed an association between
microarray expression and cancer prognosis (bladder 3/5,
blood 6/28, breast 39/83, brain 3/8, esophagus 0/1, head
and neck 0/4, kidney 0/1, lung 1/16, ovarian 0/6) with
5% significance level. Clicking the probe ID in the list
reveals a detailed report, which includes further annota-
tions for the dataset (Fig. 2A) and four intuitive visualiza-
tion panels (Fig. 2B–E). The example of the Rotterdam
cohort for DMFS depicts that patients can be dichot-
omized at the 34 percentile to give the minimum P-value
and the group with high MKI67 expression has poorer sur-
vival (Pcor = 0.0078). We found all tests but one for B-cell
lymphoma OS showed a positive correlation to poorer
survival, consistent with previous study results [40]. We
further confirmed that the expressions of other well
known proliferation markers TOP2A, PCNA and Aurora A
also showed association with poorer survival in various
tests (Additional file 2).
The second example is SIX1, emerging as a tumor-suscep-
tible gene. This homeobox gene has been shown to pro-
mote tumor progression through direct activation of
Cyclin A1 [41,42] and to associate with prognosis of late-
stage ovarian cancer [43] and hepatocellular carcinoma
[44]. It has also been reported that SIX1 can be amplified
and/or overexpressed in breast cancers [45,46]. Nonethe-
less, to our knowledge, association with breast cancer
prognosis has not yet been demonstrated. And so we
tested SIX1. For ovarian cancer, a clear association was not
observed in three tests available in PrognoScan. For this
cancer type, further subgrouping based on stage may be
needed, as reported [43]. On the other hand, SIX1 expres-
sion was positively associated with 5 out of 28 breast can-
cer tests (Fig. 3; Uppsala cohort; Pcor = 0.0002, 0.0006
and 0.0449, Uppsala+Oxford cohort; Pcor = 0.0346,
Stockholm cohort; Pcor = 0.0354) with statistical signifi-
cance, indicative of its contribution to breast cancer
PrognoScan screenshot and sample search results (part 1) Figure 1
PrognoScan screenshot and sample search results (part 1). (A) The top page is quite simple and only requires entering 
the gene identifier(s). (B) Summary table for MKI67, shown here in part (See Additional file 1 for the full table.). Column head-
ings include dataset, cancer type, subtype, endpoint, cohort, contributor, array type, probe ID, number of patients, optimal cut-
point, Pmin and Pcor. A statistically significant value of Pcor is given in red font. Each dataset has a link to the public domain where 
the raw data is archived. By clicking a probe ID in the summary table, a detailed report for the test is displayed. The table can 
be downloaded in a tab delimited file from the button at bottom.
B A
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malignancy. In addition, SIX1 expression showed nonsig-
nificant trend toward worse prognosis in the GUYT2 and
MGH cohorts (Pcor = 0.0601, 0.0729, respectively). Using
PrognoScan, SIX1 expression was correlated to breast can-
cer prognosis in multiple tests for the first time.
The third example is MCTS1, a candidate oncogene ampli-
fied in T cell lymphoma. MCTS1 in a xenograft model
causes transformation of NIH 3T3 mouse fibroblasts [47]
and increases tumorgenicity by promoting angiogenesis
and inhibiting apoptosis [48]. Similar to SIX1, prognostic
analysis of this gene has not been reported for any cancers.
PrognoScan depicted statistical significance in several
tests: blood 2/7, breast 4/21, brain 1/2, lung 2/5 (Fig. 4).
In all these 9 tests, a higher expression of MCTS1 associ-
ated with poorer survival, suggesting proactive involve-
ment of this gene in the malignancy in the cancers. Again,
this prognostic analysis was the first to show these rela-
tionships.
Discussion and conclusion
PrognoScan is a database that focuses on the prognostic
value of individual genes and differs conceptually from
gene signatures. van't Veer et al. showed that the '70 gene
signature' can predict risk of breast cancer recurrence, and
that pattern analysis of multifactorial gene signature has
greater potential for improving cancer subtype classifica-
tion and risk prediction [49]. On the other hand, the prog-
nostic value of an individual gene, for which pattern
analysis is not applicable, suggests underlying relevance of
the gene to cancer etiology and in turn stimulates
research. With the number of public cancer microarray
datasets with clinical annotation currently available, it is
reasonable to utilize those assets to link gene expression
to prognosis. Actually, Mehra et al., Paulson et al., and Kim
et al. interrogated published cancer microarray datasets to
evaluate targeted genes, GATA3, HBP1 and CUL7, respec-
tively [50-52]. In this study, candidate oncogene SIX1 was
correlated to breast cancer prognosis and MCTS1 to brain,
PrognoScan screenshot and sample search results (part 2) Figure 2
PrognoScan screenshot and sample search results (part 2). (A) Annotation table. Row headings are color-coded. For 
example, headings of details such as therapy history, sample type and pathological parameters are highlighted in yellow and 
basic attributes in blue. (B) Expression plot. Patients are ordered by the expression values of the given gene. The X-axis repre-
sents the accumulative number of patients and the Y-axis represents the expression value. Straight lines (cyan) show the opti-
mal cutpoints that dichotomize patients into high (red) and low (blue) expression groups. (C) Expression histogram. The 
distribution of the expression value is presented where the X-axis represents the number of patients and the Y-axis represents 
the expression value on the same scale as the expression plot. The line of the optimal cutpoint is also shown (cyan). (D) P-value 
plot. For each potential cutpoint of expression measurement, patients are dichotomized and survival difference between high 
and low expression groups is calculated by log-rank test. The X-axis represents the accumulative number of patients on the 
same scale as the expression plot and the Y-axis represents raw P-values on a log scale. The cutpoint to minimize the P-value is 
determined and indicated by the cyan line. The gray line indicates the 5% significance level. (E) Kaplan-Meier plot. Survival 
curves for high (red) and low (blue) expression groups dichotomized at the optimal cutpoint are plotted. The X-axis repre-
sents time and the Y-axis represents survival rate. 95% confidence intervals for each group are also indicated by dotted lines.
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blood, breast and lung cancer prognosis for the first time.
PrognoScan aims to fulfill such substantial practical
requirements.
Regarding survival analysis using publicly available
microarray datasets, several considerations exist:
1) Cohorts. Datasets come from a number of different
institutions around the world, and patient backgrounds
differ. In addition, several datasets are based on specific
subpopulations, for example, dataset GSE2034 is from
lymph node-negative breast cancers, and GSE5287 is from
cisplatin-containing chemotherapy-treated bladder can-
cers. Hence, it is possible that the specific association
between gene expression and prognosis is found in a cer-
tain cohort. To give an example, Dai et al. reported that
cell cycle genes are highly prognostic in groups with high
Kaplan-Meier plots for high and low SIX1-expressing groups in breast cancers Figure 3
Kaplan-Meier plots for high and low SIX1-expressing groups in breast cancers.
Breast cancer; Uppsala DFS (205817_at)
Breast cancer; Uppsala RFS (230911_at)
Breast cancer; Stockholm RFS (205817_at)
Breast cancer; Uppsala+Oxford DMFS (205817_at)
Breast cancer; Uppsala DFS (228347_at)
Pcor = 0.0354
Pcor = 0.0449
Pcor = 0.0002
Pcor = 0.0006
Pcor = 0.0346BMC Medical Genomics 2009, 2:18 http://www.biomedcentral.com/1755-8794/2/18
Page 8 of 11
(page number not for citation purposes)
ER expression for their age but less or nonprognostic in
other groups [53].
2) Quality of care. It has been reported that the hospital
itself could be a factor in clinical outcome [54-56]. This
means, even if cohorts were equivalent at the time of pro-
filing, subsequent care may affect the clinical course of a
patient.
3) Experimental factors. Expression measurement of
microarray is subject to various factors at the experiment
level. Microdissection (e.g. GSE1378) would reduce con-
tamination of mRNAs from non-cancer cells [57]. Forma-
lin fixation of a sample (e.g. GSE2873) influences the
quality of mRNAs [58]. Array type (e.g. Affymetrix, cDNA
microarrays) and data processing method (e.g. MAS,
RMA) can also influence gene expression measurements
[59]. In addition, it is known that a substantial number of
incorrect probes are used in microarrays [60].
4) Random error. Even though there may be no relation
between a gene expression and prognosis, false positives
may be detected by chance.
Thus, one needs to regard the results from PrognoScan in
the context of complex conditions. Currently, PrognoScan
provides curated information such as cohort, therapy his-
tory, pathological parameters and array type to aid in the
interpretation of the results. As a next step, developing an
"interpreter" for complex meta-analysis result is tempting
and we are now contemplating the challenge. In the
meantime, we will continue collecting published datasets
and will update PrognoScan every 6 months. Increased
data content will help the judgment of the robustness of
the prognostic value of a gene.
Further plans for PrognoScan also include development
of the algorithm for finding multiple cutpoints. From the
limited computational resources, cutpoint selection is
currently done for two-way (high and low) expression
grouping. For clinical practice, three-way (high, interme-
diate, and low) expression grouping can also be used.
Thus, we are trying to develop a grid search algorithm,
demonstrated as the "X-Tile" tool [61]. In summary, this
new database provides a powerful platform for evaluating
potential tumor markers and therapeutic targets, and as a
result, will accelerate cancer research.
Kaplan-Meier plots for high and low MCTS1-expressing groups in breast, lung, blood and brain cancers Figure 4
Kaplan-Meier plots for high and low MCTS1-expressing groups in breast, lung, blood and brain cancers.
Multiple Myeloma; Arkansas CSS (218163_at)
Pcor = 0.0244
AML; Munich OS (218163_at)
Pcor = 0.0002
NSCLC; Basel OS (H200011193)
Pcor = 0.015
Pcor = 0.014
NSCLC; Seoul DFS (218163_at)
Breast cancer; Mainz DMFS (218163_at)
Pcor = 0.0017
Breast cancer; Stckholm RFS (218163_at)
Pcor = 0.0053
Breast cancer; Uppsala DSS (218163_at)
Pcor = 0.003
Breast cancer; Uppsala DFS (218163_at)
Pcor = 0.0002
Glioma; MDA OS (218163_at)
Pcor = 0.0378BMC Medical Genomics 2009, 2:18 http://www.biomedcentral.com/1755-8794/2/18
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Availability and requirements
PrognoScan requires nothing other than a web browser
and is available from the server at Kyushu Institute of
Technology (KIT): http://gibk21.bse.kyutech.ac.jp/Prog
noScan/index.html.
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